Cartesian Therapeutics, Inc.
RNAC
$10.50
-$0.07-0.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 49.64% | -62.40% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.64% | -62.40% | -- | -- | -- |
| Cost of Revenue | -31.61% | -57.21% | -- | -- | -- |
| Gross Profit | 84.89% | -117.44% | -- | -- | -- |
| SG&A Expenses | -15.03% | -5.90% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.87% | -43.81% | -- | -- | -- |
| Operating Income | 52.26% | -34.55% | -- | -- | -- |
| Income Before Tax | 67.69% | -12,487.26% | -- | -- | -- |
| Income Tax Expenses | 101.51% | -3,019.87% | -- | -- | -- |
| Earnings from Continuing Operations | 64.76% | -16,364.63% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.76% | -16,364.63% | -- | -- | -- |
| EBIT | 52.26% | -34.55% | -- | -- | -- |
| EBITDA | 53.28% | -39.63% | -- | -- | -- |
| EPS Basic | 78.16% | -520.29% | -- | -- | -- |
| Normalized Basic EPS | 91.12% | -317.30% | -- | -- | -- |
| EPS Diluted | 78.06% | -520.48% | -- | -- | -- |
| Normalized Diluted EPS | 91.02% | -317.79% | -- | -- | -- |
| Average Basic Shares Outstanding | 233.80% | 217.83% | -- | -- | -- |
| Average Diluted Shares Outstanding | 238.96% | 224.77% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |